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BACKGROUND: Left atrial appendage occlusion with WATCHMAN has emerged 
as viable alternative to vitamin K antagonists in randomized controlled trials. 
Evaluating real-life clinical outcomes in atrial fibrillation patients receiving the 
WATCHMAN left atrial appendage closure technology was designed to collect 
prospective multicenter outcomes of thromboembolic events, bleeding, and 
mortality for patients implanted with a WATCHMAN in routine daily practice.
METHODS: One thousand twenty patients with a WATCHMAN implant procedure 
were prospectively followed in 47 centers. Left atrial appendage occlusion indication 
was based on the European Society of Cardiology guidelines. Follow-up and 
imaging were performed per local practice up to a median follow-up of 2 years.
RESULTS: Included population was old (age 73.4±8.9 years), at high risk for stroke 
(311 prior ischemic stroke/transient ischemic attack and 153 prior hemorrhagic 
stroke) and bleeding (318 prior major bleeding), with CHA2DS2-VASc score ≥5 
in 49%, hypertension, abnormal renal/liver function, stroke, bleeding history 
or predisposition, Labile international normalized ratio, elderly, drugs/alcohol 
concomitantly ≥3 in 40% and oral anticoagulation contraindication in 72%. 
During follow-up, 161 patients (16.4%) died, 22 strokes were observed (1.3/100 
patient-years, 83% reduction versus historic data), and 47 major nonprocedural 
bleeding events (2.7/100 patient-years, 46% reduction versus historic data). 
Stroke and bleeding rates were consistently lower than historic data in those 
with prior ischemic (−76% and −41%) or hemorrhagic (−81% and 67%) stroke 
and prior bleeding (−85% and −30%). Lowest bleeding rates were seen in 
patients with early discontinuation of dual antiplatelet therapy. Patients with early 
discontinuation of antithrombotic therapy showed lower bleeding rates, while they 
were highest for those with prior bleeding. Device thrombus was observed in 34 
patients (4.1%) and was not correlated to drug regimen during follow-up (P=0.28).
CONCLUSIONS: During the complete 2-year follow-up of Evaluating Real-
Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN 
Left Atrial Appendage Closure Technology, patients with a WATCHMAN 
left atrial appendage occlusion device had consistently low rates of stroke 
and nonprocedural bleeding, although most were contraindicated to oral 
anticoagulation and used only single antiplatelet therapy or nothing.
CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: 
NCT01972282.
VISUAL OVERVIEW: A visual overview is available for this article.
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Over the last decade, left atrial appendage occlu-sion (LAAO) has become an attractive alternative to reduce the risk of stroke in patients with non-
valvular atrial fibrillation (AF), especially when long-term 
oral anticoagulation (OAC), either a vitamin K antagonist 
(VKA) or a novel agent (NOAC), is not suitable or haz-
ardous. The recent meta-analysis of the final 5-year out-
come data of the randomized controlled trials PROTECT-
AF (Percutaneous Closure of the Left Atrial Appendage 
Versus Warfarin Therapy for Prevention of Stroke in Pa-
tients With Atrial Fibrillation)  and PREVAIL (Prospective 
Randomized Evaluation of the WATCHMAN Left Atrial 
Appendage Closure Device in Patients With Atrial Fibril-
lation Versus Long-Term Warfarin Therapy)  shows that 
WATCHMAN LAAO (Boston Scientific Corporation, St 
Paul, MN) was noninferior to warfarin therapy for the 
prevention of stroke, while nonprocedural bleeding 
and mortality were lower in the device arm.1 Based on 
these randomized controlled trial and smaller registry 
data, WATCHMAN LAAO has become part of routine 
reimbursed health care options for stroke prevention in 
many countries around the world, including large ge-
ographies such as the United States and Germany.
In clinical guidelines, however, LAAO still has a class 
2b indication and is primarily recommended for those 
patients who have survived or are deemed at risk for 
life-threatening bleeding in the European Society of 
Cardiology guidelines of 2012 and 2016.2 Evidence for 
the benefits of LAAO in this population only came from 
small registries such as the ASAP trial  (ASA Plavix Fea-
sibility Study With WATCHMAN Left Atrial Appendage 
Closure Technology), that showed >70% lower stroke 
rate in 150 patients with WATCHMAN compared with 
expected if OAC would have been used.3 The prospective 
multicenter, multinational EWOLUTION registry (Evalu-
ating Real-Life Clinical Outcomes in Atrial Fibrillation 
Patients Receiving the WATCHMAN Left Atrial Append-
age Closure Technology) was designed to obtain peri-
procedural and outcome data over a 2-year time frame 
from >1000 patients with nonvalvular AF at high risk for 
stroke in everyday clinical practice outside of controlled 
trials.4 Periprocedural outcome data showed a high 
implant success with low adverse events rates, while the 
1-year interim analysis showed promising outcomes for 
efficacy and safety.5,6 The present article reports on the 
complete 2-year follow-up data for the entire patient 
cohort. Overall safety and efficacy are presented, as well 
as for subgroups at very high risk for stroke and bleed-
ing including patients with prior ischemic and hemor-
rhagic stroke and those with a prior major bleeding.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request. The 
outline of the study has been described in detail in the design 
article4 and the first report on periprocedural outcomes5 and 
1-year outcome data.6 The study adhered to international 
rules for scientific studies, the Helsinki principles, with local 
ethics committee approval in all participating centers per local 
regulations. All subjects provided informed consent before 
the procedure. Boston Scientific Corporation provided fund-
ing for the study. In brief, EWOLUTION was designed as a 
multicenter, prospective, nonrandomized cohort study aim-
ing to include over 1000 patients. Subjects were recruited 
at each participating center per physician’s decision if they 
were eligible to receive the WATCHMAN device according 
to the appropriate local and international guidelines, were 
not participating in another trial, were not pregnant when 
of childbearing age, and were willing, able, and of legal 
age to provide informed consent. All implanting physicians 
underwent a thorough training and certification program to 
ensure an appropriate level of expertise to minimize patient 
risk. Follow-up for subjects was not prespecified but based on 
each institution’s standard practice, generally a clinical visit 
between 1 and 3 months postprocedure, LAA imaging to 
assess residual flow around and thrombus on the device, and 
annual follow-up visits. All data collection and adverse event 
reporting were performed directly by the individual sites and 
captured in a standardized central database. Adverse event 
adjudication was based on ISO 14155 and the MEDDEV 
2.7/3 12/2010 and included serious events such as perfora-
tion, tamponade, embolism, neurological events, thrombosis, 
and bleeding. Bleeding was scored according to the BARC 
(Bleeding Academic Research Consortium) criteria,7 align-
ing with definition of major bleeding (which includes fatal 
and life threatening) described by Tzikas et al8 in the con-
sensus document on definitions, end points, and data col-
lection requirements. Stroke was classified in accordance 
to the criteria described by Leon et al.9 All data and events 
were adjudicated and entered into the central database by 
the local investigators. Events and relevant source documents 
WHAT IS KNOWN?
• The left atrial appendage is the most important 
source of thromboembolism and stroke in patients 
with nonvalvular atrial fibrillation.
• Mechanical closure with WATCHMAN has been 
proven an effective alternative to vitamin K antag-
onists for stroke-protection in randomized con-
trolled trials.
WHAT THE STUDY ADDS?
• Evaluating real-life clinical outcomes in atrial fibril-
lation patients receiving the WATCHMAN left atrial 
appendage closure technology confirms favorable 
outcomes during 2-year follow-up in 1020 routine 
clinical practice patients, most of them with a con-
traindication for anticoagulation.
• Thromboembolism and bleeding rates are low, 
even in high-risk patient cohorts with prior stroke, 
prior intracranial hemorrhage, and prior bleeding.
• Further lowering of anticoagulation reduces bleed-
ing rate while retaining efficacy.
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were additionally reviewed by the Sponsor Medical Safety 
Group. The Medical Safety Group includes physicians with 
expertise in Electrophysiology and Cardiology, as well as other 
healthcare professionals with the necessary therapeutic and 
subject matter expertise to evaluate the events. Centers were 
required to provide additional information in case of dis-
agreement. At study end, the adjudication by the investiga-
tors and the Medical Safety Group was 100% aligned. All 
centers were also monitored by an outside contract research 
organization on an ongoing basis. One center with only 
one patient enrolled was only visited once. All other centers 
received onsite monitoring between 2 and 5 times depend-
ing on number of patients enrolled and compliance review. 
Data review in the study database was performed for 100% 
of forms. Source data verification was performed at onsite 
visits and for relevant adverse events source documents were 
requested at the sites and reviewed remotely. These included 
at a minimum all-cause death, all strokes, transient ischemic 
attack (TIA), systemic embolism (SE), and all adverse events 
occurring within 7 days of the implant, regardless of whether 
event was judged serious and whether related or not to the 
device/procedure. Boston scientific provided supervision over 
the trial and the source data (E. Vireca), as well as statistical 
support. The 2 coauthors employed by Boston Scientific (E. 
Vireca and Dr Stein) were involved in trial design and review 
of the article. Individual sites reported on transesophageal 
echocardiography (TEE) findings. TEE images from the implant 
and first follow-up were sampled in 25% of sites and about 
10% of patients by the sponsor, to rule out discrepancies with 
the database content. As no irregularities were detected no 
additional review was performed.
Statistical Analysis
The objective of the study was to obtain data on procedural 
success and complications, and long-term patient outcomes, 
including bleeding and incidence of stroke/TIA/SE, and the 
sample size was based on a desire to obtain sufficiently 
precise estimates of rare adverse events and not on power 
requirements for a formal hypothesis test. Rates of stroke/
bleeding events are calculated as a number of events per 
100 patient-years. The individual patient annual risk for 
stroke and bleeding was recorded based on each subject’s 
CHA2DS2-VASc (congestive heart failure, hypertension, 75 
years of age and older, diabetes mellitus, previous stroke or 
transient ischemic attack, vascular disease, 65 to 74 years 
of age, female; left ventricular ejection fraction) and HAS-
BLED (hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile international nor-
malized ratio, elderly, drugs/alcohol concomitantly) score 
and then the average risk score for the study population 
was calculated. Annual risk of stroke and bleeding was 
then extrapolated from published risk score literature10,11 
to determine relative risk reductions (RRRs). For stroke, TIA, 
and SE, this was compared with patients not using any form 
of anticoagulation matched for CHADS-VASc score,10 while 
for bleeding this was compared with patients using VKAs 
matched for HAS-BLED score.11 Mortality rate is calculated 
via the Kaplan-Meier method to account for censoring. Rate 
of device-related thrombus (DRT) is calculated as a propor-
tion of patients who had LAA imaging available. P values are 
based on log-rank tests for time-to-event analysis and Fisher 
exact test for binomial proportions. Three separate higher-
risk cohorts were defined as being patients with a history of 
stroke or TIA, patients with a history of hemorrhagic stroke 
and patients with a history of major bleeding. These cohorts 
were also compared against the same historical control data.
RESULTS
Patient Characteristics
Enrollment opened in October 2013 and was completed 
in May 2015. Details of the periprocedural outcomes and 
1-year interim data were published previously.5,6 A total 
of 1020 subjects underwent a WATCHMAN implant 
procedure in a total of 47 centers in 13 countries (Fig-
ure 1). The inclusion rate ranged from 1 to 86 enrolled 
subjects per site, and at least 39/47 sites (83%) enrolled 
consecutive patients, with no apparent differences 
about occurrence of SAEs (P=0.253).6 Seventy-eight 
percent of the implanting physicians had <2 years of 
experience with the WATCHMAN device and performed 
75% of the study procedures. The median follow-up in 
the study was 732 days (interquartile range: 677–757).
Baseline demographics and risk factors are summa-
rized in Table  1. Baseline CHA2DS2-VASc was 4.5±1.6 
(historic stroke risk of 7.2% per patient-years in the 
absence of anticoagulation therapy10) and HAS-BLED 
2.3±1.2 (historic bleeding risk of 5.0% per patient-years 
in the presence of VKA therapy11). A HAS-BLED score ≥3 
was present in 40% of patients. Mean age was 73.4±8.9 
years, prior ischemic stroke/TIA was present in 30.5%, 
15.1% had previous hemorrhagic stroke, and 31.3% 
had a history of major bleeding; 72.2% of patients were 
deemed contraindicated for OAC. Data were not always 
provided on the reasons for a contraindication. It is pos-
sible that some of these patients may have had relative 
versus absolute contraindications to the drugs, but nev-
ertheless, they were deemed unsuitable for short- or 
long-term OAC treatment at the time of implant.
Mortality During 2-Years Follow-Up
Of the 1020 patients that underwent a WATCHMAN 
LAAO implant procedure, 161 (Kaplan-Meier event 
rate 16.4%, CI, 13.8%–19.3%) died as depicted in 
Figure 1. A list of the reasons for death is provided in 
Table 2. Noncardiovascular reasons were miscellaneous 
and most common (7.4%), while 4.5% had a cardio-
vascular reason (most common heart failure), 1.0% 
had a fatal bleeding, and 2.9% remained unknown. 
In the 10 patients with death because of bleeding, 6 
were gastrointestinal while the other 4 were cerebral. 
These patients were most commonly on dual antiplate-
let therapy (DAPT; 7), while 1 was on single antiplatelet 
therapy (SAPT), 1 on VKA, and 1 was using no antico-
agulation at the time of the event.
D
ow
nloaded from
 http://ahajournals.org by on July 11, 2019
Boersma et al; EWOLUTION WATCHMAN LAAO
Circ Arrhythm Electrophysiol. 2019;12:e006841. DOI: 10.1161/CIRCEP.118.006841 March 2019 4
Antithrombotic Regimen
At hospital discharge after successful WATCHMAN 
LAAO, 16% of patients were using VKA, 11% NOAC, 
60% DAPT, 7% SAPT, and 6% no anticoagulation at 
all (Figure 2A). After the first discontinuation of anti-
coagulants only 8% remained on VKA or NOAC, while 
26% were on DAPT, 58% on SAPT, and 8% were using 
nothing. The median (interquartile range) time to dis-
continue OAC was 68 (50–102) days, for DAPT it was 
158 (74–195) days. At the final follow-up of 2 years, 
8% of active patients were still on OAC, 7% were on 
DAPT, 71% were on SAPT, while 14% were not using 
any anticoagulant. The timing of conversion to a final 
treatment of SAPT or nothing is shown in Figure 2B: 
46% had switched at 6 months, 75% at 1 year, and 
95% at 2 years. Table 3 shows the antithrombotic med-
ication for the higher-risk cohorts with prior ischemic 
and hemorrhagic stroke and major bleeding.
The use of different drug types was fairly consis-
tent for all subgroups directly after the implant. Only 
in patients with prior hemorrhagic stroke less patients 
were on OAC and more were on SAPT/nothing. At 2 
years, in all cohorts, the use of OACs and DAPT was 
only around 15%.
Device Thrombus
The main reason to use any type of anticoagulant 
after a WATCHMAN implant is the risk of DRT, which 
could in turn be related to thromboembolic events. 
In the 835 patients with imaging of the LAA, a total 
of 34 cases of DRT (4.1%) were observed with an 
average 1.4 per patient TEE or computed tomogra-
phy imaging procedures. Of these 34 cases, 31 were 
observed at first imaging usually within 90 days after 
the procedure (median 54 days, interquartile range 
42–111). The majority (21, 2.5%) were nonmobile 
laminar type of thrombus, some (9, 1.1%) were 
mobile and pedunculated, and a few (4, 0.5%) were 
not specified. No statistical relation could be found 
between DRT and type of anticoagulation (Figure 3), 
although only patients on NOAC, VKA, or DAPT had 
laminar nonmobile types, and mobile types were seen 
in all but VKA patients.
Treatment of DRT was initiated in 21/34 of patients 
while no action was taken in the remaining 13. Resolu-
tion was confirmed in 18/21 of treated patients and 
9/13 of untreated. The outcome of 6 DRT is unknown, 
as the patients had no LAA imaging performed after 
thrombus was discovered, however, no thromboembol-
ic event occurred in these patients. One DRT was not 
resolved at the time of study end, the thrombus was 
detected at first TEE (90 days) while on warfarin and 
treatment remain unchanged throughout the study, 
but did not solve the thrombus.
One patient experienced a major gastrointestinal 
bleeding because of the medication change (rivaroxa-
ban 15 mg added to preexisting DAPT), which resolved 
within 10 days.
In all patients with thrombus detected at routine 
LAA imaging, there were no subsequent reports of 
adverse events such as stroke, TIA, or embolism during 
a median follow-up period of 21 months (interquartile 
range, 16–23) following DRT detection. In 21 patients 
with stroke in whom LAA imaging was performed, 1 
Figure 1. Flowchart of the patients in the 
EWOLUTION study (Evaluating Real-Life 
Clinical Outcomes in Atrial Fibrillation Pa-
tients Receiving the WATCHMAN Left Atrial 
Appendage Closure Technology).  
CT indicates computed tomography; FU, 
follow-up; pts, patients; TEE, transesophageal 
echocardiography; and yrs, years.
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instance of DRT was observed. No significant differ-
ence in annual rates of stroke/TIA/SE was observed in 
patients with or without DRT (DRT 1.7 versus no-DRT 
2.2, P=0.805).
Bleeding Events
During the 2-year follow-up, a nonprocedural major 
bleeding was observed in 47 patients, of which 10 
were fatal events. Compared with a historical bleed-
ing risk of 5.0 with the EWOLUTION distribution of 
HAS-BLED scores, the actual bleeding rate of 2.7/100 
patient-years conferred a 46% RRR (Figure  4A). In 
patients with HAS-BLED <3 (Figure 5) the reduction 
was slightly larger (612 patients, historic 3.6 versus 
actual 1.8 per 100 patient-years, RRR 50%) than in 
those with HAS-BLED of 3 or more (408 patients, 
historic 7.1 versus actual 4.2 per 100 patient-years, 
RRR 41%).
A propensity-adjusted analysis was performed of 
the patients prescribed DAPT postimplant to assess the 
impact of DAPT duration on bleeding and thrombo-
embolic events. The cohort was separated in patients 
discontinuing DAPT ≤105 days (189 patients) versus 
those that switched >105 days (379 patients). Pro-
pensity matching was performed for CHA2DS2-VASc 
score, HAS-BLED score, total number of partial device 
recaptures across all attempted devices, number of 
full device recaptures, left ventricular ejection fraction 
Table 1. Baseline Patient Characteristics
Characteristic All Patients (N=1025)
Contraindicated 72.2% (740/1025)
Age at time of consent, y
  Mean±SD 73.4±8.8
  Age >75 50.7% (520/1025)
  Sex (Female) 40.1% (411/1025)
CHA2DS2-VASc score 4.5±1.6
  <1 1.8% (1811025)
  2–3 25.2% (258/1025)
  ≥4 73.1% (749/1025)
HAS-BLED score 2.3±1.2
  <3 60.0% (615/1025)
  ≥3 40.0% (410/1025)
NYHA class
  I 10.3% (36/348)
  II 55.5% (193/348)
  III 32.2% (112/348)
  IV 2.0% (7/348)
CHF 34.1% (350/1025)
LVEF ≤40% 13.2% (135/1023)
Vascular disease 42.2% (433/1025)
Abnormal renal function 15.8% (162/1025)
Abnormal liver function 4.3% (44/1025)
Hypertension 86.6% (888/1025)
Diabetes mellitus 29.7% (304/1025)
Prior major bleeding or predisposition 
to bleeding
38.6% (396/1025)
CHA2DS2-VASc indicates CHF, hypertension, 75 y of age and older, diabetes 
mellitus, previous stroke or transient ischemic attack, vascular disease, 65–74 
y of age, female; CHF, congestive heart failure; EWOLUTION, Evaluating Real-
Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN 
Left Atrial Appendage Closure Technology; HAS-BLED, hypertension, 
abnormal renal/liver function, stroke, bleeding history or predisposition, labile 
international normalized ratio, elderly, drugs/alcohol concomitantly; LVEF, left 
ventricular ejection fraction; and NYHA, New York Heart Association.
Table is adapted from Boersma et al.6 Copyright © 2017 Boersma et al. 
Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is an open 
access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Table 2. Summary of Fatal Events at 2-Year Follow-Up
Type of Death Total No. of Events
Bleeding 10 (1.0%)
  Gastrointestinal bleeding 6
  Hemorrhagic stroke 2
  Cranial bleed 1
  Subdural hematoma 1
Cardiovascular 46 (4.5%)
  Heart failure 19
  Myocardial infarction 5
  Cardiac arrest 4
  Cardiogenic shock, low-output syndrome 4
  Pulmonary embolism 3
  Aortic dissection 2
  Cerebral air embolism* 1
  Aortic stenosis 1
  Peripheral vascular disease 1
  Ventricular fibrillation 1
  Ventricular tachycardia 1
Noncardiovascular 75 (7.4%)
  Pulmonary 18
  Systemic infection 14
  Cancer 11
  Multiorgan failure 10
  Gastrointestinal 8
  Renal 7
  Integumentary 3
  Neurological 1
  Physical trauma 1
  Musculoskeletal 1
  Immune 1
Unknown 30 (2.9%)
Total 161 (15.8%)
*Related to implant of the device.
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(<30%, 30%–50%, or >50%), AF pattern (paroxysmal, 
persistent, permanent, paced, sinus rhythm, and other), 
and postimplant LAA seal (complete seal, jet size ≤5 
mm, or jet size >5 mm). In patients with early lower-
ing of anticoagulation, propensity-adjusted bleeding 
rates were lowest at 1.1%, while bleeding rates were 
higher for late discontinuation with 3.5%, while there 
was no difference in the combined rates of ischemic 
stroke, TIA, SE, and DRT in the 2 cohorts (3.9% and 
3.7%). Although this propensity-adjusted analysis did 
not reach statistical significance (P=0.122), it suggests 
that a shorter DAPT duration may be as safe as a longer 
course, and it could be a preferred strategy in very high-
risk patients to minimize the risk of bleeding events.
Stroke, TIA, and SE
The event rates for ischemic stroke, TIA, and SE can 
be seen in Figures  6A and 7A. The complete cohort 
had a historical ischemic stroke risk of 7.2/100 patient-
years and composite risk of ischemic stroke/TIA/SE of 
10.1/100 patient-years. The observed stroke rate was 
Figure 2. Overview of anticoagulation 
use during the EWOLUTION study 
(Evaluating Real-Life Clinical Outcomes in 
Atrial Fibrillation Patients Receiving the 
WATCHMAN Left Atrial Appendage Closure 
Technology).  
A, Anticoagulation after WATCHMAN left atrial 
appendage occlusion (LAAO) during 2-y follow-
up; (B) timing of final switch to single antiplate-
let therapy (SAPT) or nothing after WATCHMAN 
LAAO. DAPT indicates dual antiplatelet therapy; 
FU, follow-up; and OAC, oral anticoagulation.
Table 3. Summary of Risk Factors and Postimplant Medications for the Entire EWOLUTION Population and the 3 Higher-Risk 
Cohorts: Prior Stroke/TIA, Prior Hemorrhagic Stroke, Prior Major Bleeding
Group N CHA2DS2-VASc HAS-BLED
Postimplant meds
OAC SAPT/None DAPT
EWOLUTION full cohort 1020 4.5 2.3 27% 14% 60%
  Hx ischemic stroke/TIA 311 5.5 2.6 35% 15% 50%
  Hx hemorrhagic stroke 153 5.4 2.8 11% 27% 62%
  Hx major bleeding 318 4.8 3.2 15% 17% 67%
CHA2DS2-VASc indicates congestive heart failure, hypertension, 75 y of age and older, diabetes mellitus, previous stroke or transient ischemic 
attack, vascular disease, 65–74 y of age, female; DAPT, dual antiplatelet therapy; EWOLUTION, Evaluating Real-Life Clinical Outcomes in Atrial 
Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology; HAS-BLED, hypertension, abnormal renal/liver function, 
stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly; Hx, history; LVEF, left 
ventricular ejection fraction; OAC, oral anticoagulation; SAPT, single antiplatelet therapy; and TIA, transient ischemic attack.
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1.3/100 patient-years, conferring a reduction of 83%. 
For the combined end point, ischemic stroke/TIA/SE, 
the observed rate was 2.0/100 patient-years, conferring 
a risk reduction of 80%. Of interest, when the cohort 
was divided in those with lower (n=118) and those 
with higher risk (n=902), no ischemic strokes, TIA, or 
SE were observed in any patient with a CHA2DS2-VASc 
score of <3 (Figure 8). In the group with a CHA2DS2-
VASc score of 3 or more, the ischemic stroke rate was 
82% lower than expected (7.9 versus 1.4/100 patient-
years), while the composite of ischemic stroke/TIA/SE 
was 79% lower than expected (11.1 versus 2.3 per 
100/patient-years).
Overall, 46 thromboembolic events occurred in 
35 patients, of which 22 were ischemic stroke (5 dis-
abling), 23 were TIA, and 1 was an SE. At the time of 
the first thromboembolic event, 17% were on (N)OAC, 
26% on DAPT, 43% on SAPT, and 14% on no medica-
tions. In 43% of the index events, anticoagulation was 
intensified by starting a (N)OAC or adding (stronger) 
APT, while in the remainder the type of anticoagula-
tion remained unchanged (48%) or was lowered/
stopped (9%) despite the event, possibly to prevent 
hemorrhagic transformation. Nine patients had sub-
sequent events, regardless of intensifying (4), keeping 
(3), or stopping anticoagulation (2). Two patients even 
had 3 events, despite remaining on DAPT in one, and 
switching from OAC plus acetylsalicylic acid (ASA) to 
OAC plus clopidogrel in the other. No significant rela-
tionship could be established between the events or 
the type of drug use.
Outcomes in Higher-Risk Patient 
Subgroups
Specific subgroups of interest were patients with a 
history of either stroke/TIA, or hemorrhagic stroke, or 
major bleeding. Prior stroke/TIA was present in 311 
of the 1025 patients (30.5%) and compared with the 
rest of the study population was less common in the 
elderly over 65 years (76.0% versus 83.8%, P=0.004), 
while CHA2DS2-VASc of 5.5±1.4 and HAS-BLED scores 
of 2.6±1.3 were high. The observed ischemic stroke 
rate was 2.3/100 patient-years (76% less than his-
toric controls), with a rate of ischemic stroke/TIA/SE 
of 3.9/100 patient-years (71% less than historic con-
trols). Nonprocedural major bleeding rate of 3.2/100 
Figure 3. Rate of device-related thrombus by anticoagulant use.  
(D)APT indicates (dual) antiplatelet therapy; NOAC, novel oral anticoagulation; 
and VKA, vitamin K antagonist (warfarin).
Figure 4. Major bleeding rates for the overall population and high risk subgroups.  
A, Overall population; (B) patients (pts) with history of stroke/transient ischemic attack (TIA); (C) pts with history of hemorrhagic stroke; and (D) pts with history of 
major bleed. EWOLUTION indicates Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure 
Technology; Hx, history; RRR, relative risk reduction; and VKA, vitamin K antagonist.
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patient-years was 41% lower than expected (Fig-
ures 4B, 6B, and 7b).
Compared with the rest of the population, the 
patients with a prior hemorrhagic stroke (n=153) were 
more often male (69.7% versus 58.2%, P=0.008) 
and were older (age>65 years, 91.0% versus79.8%, 
P=0.001), had less LV dysfunction (7.1% versus 14.3%, 
P=0.014), less vascular disease (33.5% versus 43.8%, 
P=0.0174), and less prior major bleeding/predisposi-
tion to bleed (25.2% versus 41.0%, P=0.0002). This 
cohort also had a high CHA2DS2-VASc (5.4±1.2) and 
HAS-BLED score (2.8±0.9). Nevertheless, the observed 
rates for stroke, embolism, and bleeding were as low 
as 1.8/100 patient-years (81% RRR), 2.6/100 patient-
years (80% RRR), and 1.8/100 patient-years (67% RRR) 
(Figures 4C, 6C, and 7C).
The final cohort to discuss is the one with 318 
patients with a prior major bleeding. Their CHA2DS2-
VASc score was 4.8 with a HAS-BLED of 3.2, conferring 
a very high risk of both stroke and bleeding. At 2 years, 
actual stroke rate was 1.2/100 patient-years (85% RRR), 
stroke/TIA/SE rate was 1.9/100 patient-years (82% RRR), 
while bleeding occurred at a rate of 4.5/100 patient-
years (30% RRR; Figures 4D, 6D, and 7D).
DISCUSSION
EWOLUTION is the largest prospective real-world registry 
on WATCHMAN and the only study in its kind reporting 
on 2-year follow-up outcomes of LAA closure to date. 
The results reinforce the data observed after 1-year fol-
low-up,6 showing a low overall stroke, TIA, and SE rate, 
which was 80% lower than predicted based on historic 
data in patients with a similar risk profile not using anti-
coagulation. When we compare the outcome data for 
stroke to prior WATCHMAN trials, such as PROTECT-AF, 
PREVAIL, and the CAP registries, these are completely in 
line and consistently low.1The discontinuation of DAPT 
and (N)OAC in 85% of the patients at 2 years was accom-
Figure 5. Major bleeding after WATCHMAN left atrial appendage oc-
clusion (LAAO) by hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile international normalized ratio, 
elderly, drugs/alcohol concomitantly (HAS-BLED) score censored at 3.  
EWOLUTION indicates Evaluating Real-Life Clinical Outcomes in Atrial Fibril-
lation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Tech-
nology; RRR, relative risk reduction; and VKA, vitamin K antagonist.
Figure 6. Ischemic stroke rates for the overall population and high risk subgroups. 
A, Overall population; (B) patients (pts) with history of stroke/transient ischemic attack (TIA); (C) pts with history of hemorrhagic stroke; and (D) pts with history of 
major bleed. CHA2DS2-VASc indicates congestive heart failure, hypertension, 75 y of age and older, diabetes mellitus, previous stroke or transient ischemic attack, 
vascular disease, 65–74 y of age, female; EWOLUTION, Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial 
Appendage Closure Technology; Hx, history; and RRR, relative risk reduction.
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panied by a 46% lower major bleeding rate compared 
with historic controls. Not surprisingly for this higher-risk 
patient population contraindicated for anticoagulation, 
161 patients died (15.7%), 1.8% withdrew, and 4.1% 
of patients were lost to follow-up during the 2-year 
study period. There were no late events like secondary 
leakage, device embolization, or other events associated 
with the device. In the AVERROES trial (Apixaban Versus 
Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation 
Patients Who Have Failed or Are Unsuitable for Vitamin 
K Antagonist Treatment),12 warfarin contraindicated AF 
patients with a lower CHA2DS2-VASc score had a stroke 
rate of 1.6% on apixaban, while in the recent GARFIELD 
registry (Global Anticoagulation Registry in the Field),13 
AF patients with a CHA2DS2-VASc of 3.0 showed a 
stroke rate of 1.3 per 100 patient-years. Despite dif-
ferences in design and population, these outcomes are 
comparable to EWOLUTION, and show that in this real-
world cohort of all-comers, WATCHMAN LAAO is a very 
effective and safe alternative for prevention of thrombo-
embolic events in patients with nonvalvular AF at high 
risk for stroke and bleeding.
Figure 7. Ischemic stroke/transient ischemic attack (TIA)/systemic embolism (SE) rates for the overall population and high risk subgroups. 
A, Overall population; (B) patients (pts) with history of stroke/TIA; (C) pts with history of hemorrhagic stroke; and (D) pts with history of major bleed. CHA2DS2-
VASc indicates congestive heart failure, hypertension, 75 y of age and older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65–74 
y of age, female; EWOLUTION, Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure 
Technology; Hx, history; and RRR, relative risk reduction.
Figure 8. Overall rates for stroke, tran-
sient ischemic attack (TIA), and systemic 
embolism (SE) by congestive heart failure, 
hypertension, 75 y of age and older, dia-
betes mellitus, previous stroke or transient 
ischemic attack, vascular disease, 65 to 
74 y of age, female (CHA2DS2-VASc) score 
censored at 3.  
EWOLUTION indicates Evaluating Real-Life Clini-
cal Outcomes in Atrial Fibrillation Patients Re-
ceiving the WATCHMAN Left Atrial Append-
age Closure Technology.
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Anticoagulation and Thromboembolism
The evidence that WATCHMAN LAAO can be a safe 
alternative to OAC comes from the randomized con-
trolled trials PROTECT-AF and PREVAIL showing nonin-
feriority for stroke, TIA, and SE in patients that were tol-
erant to OAC treatment but had reason to seek for an 
alternative in the long-term.1 The patients in the LAAO 
arm used ASA and warfarin for 45 days, then DAPT 
until 6 months, and then ASA for life. In real-world 
populations, LAAO is usually sought as an alternative 
dictated by necessity in patients with a contraindication 
for OAC, which is the only recommended indication in 
the European Society of Cardiology guidelines.2 Such 
patients cannot adopt a harsh anticoagulation scheme 
and usually end up using only APT or nothing at all. In 
EWOLUTION, 72% of patients were deemed unsuitable 
for OAC and switched to (D)APT or nothing immedi-
ately after WATCHMAN implant. After 3 to 6 months, 
66% changed to SAPT or nothing, while at study end 
84% of the active patients were using SAPT or nothing. 
Despite this lower anticoagulation scheme, outcomes 
for thromboembolism were favorable and preserved 
over time. Based on the data from EWOLUTION, the 
recommended anticoagulation scheme after WATCH-
MAN implant outside of the United States has been 
lowered to a minimum of 3 months of DAPT and ASA 
up to 1 year.
The main reason to eliminate OAC and further 
decrease APT is the evidence that this has a positive 
effect on major bleeding rates. In post hoc analyses of 
PROTECT-AF, PREVAIL, and the CAP registries, it was 
observed that after discontinuation of warfarin at 45 
days, bleeding rates in the WATCHMAN arm were only 
half of those in the warfarin arm, and dropped another 
50% after discontinuation of DAPT.14 As reduction of 
bleeding events is a major goal of WATCHMAN LAAO 
treatment, it seems desirable to minimize any form 
of anticoagulation. Conversely, reduction of the peri-
implant anticoagulation could adversely affect DRT for-
mation, which is feared as possible hallmark of embolic 
events. In a recent meta-analysis,15 an average of 3.7% 
DRT was observed with WATCHMAN and AMULET 
devices, with no clear predictors or underlying mech-
anisms. In PROTECT-AF, the rate of WATCHMAN DRT 
under optimal anticoagulation was 5%, while a recent 
reevaluation of the TEE data suggested a relationship 
between stroke and DRT.16 In the French RELAXAO reg-
istry  (Registry on Real-Life Experience With Left Atrial 
Appendage Occlusion),17 DRT was observed in up to 
7.7%, while 4 patients with DRT also had later stroke 
and 1 patient with stroke also had later DRT. In EWOLU-
TION, DRT in 4.1% of patients was never related to lat-
er stroke, and only 1 patient with a stroke was found 
to have a DRT. Of note, in EWOLUTION most DRT were 
of the nonmobile laminar type which may account for 
the lower embolic propensity compared with the oth-
er studies.16,17 No relationship was observed between 
intensity of anticoagulation during the first 3 to 6 
months and the presence of DRT. Similar small cohort 
registries observed similar favorable outcomes with a 
shorter period of dual antiplatelet [(D)APT] (ie, 6 weeks) 
or single APT [(S)APT] right after implant particularly in 
patients with high bleeding risk.18,19 Future randomized 
studies are needed to show if APT can even be lower 
and shorter with both low thromboembolic and low 
DRT rates.
Patients with AF who have suffered a prior isch-
emic stroke constitute a special population as they are 
the living proof of the increased thromboembolic risk. 
Patients with AF and prior hemorrhagic stroke are liv-
ing proof of the risks involved in classic stroke preven-
tion, especially if it occurred while using anticoagulants. 
Although there may be competing risks that are not 
treated by LAAO, both patient categories could ben-
efit from LAAO as alternative or adjunctive therapy to 
anticoagulation. In EWOLUTION, 311 patients had his-
tory of ischemic stroke or TIA and 153 had history of 
hemorrhagic stroke. Despite having a high stroke risk, 
the actual stroke rate in both groups was very low and 
in line with the total cohort. Interestingly, in the isch-
emic stroke cohort, slightly more patients were on (N)
OAC therapy in the first period after implant, although 
most of them also changed to APT/nothing over time. 
The stroke reduction was slightly lower than for the 
total population, which could be because of compet-
ing stroke risk factors. It seems conceivable that in this 
cohort a future hybrid strategy of LAAO with low dose 
(N)OAC could combine the best of both worlds and 
reduce stroke rates even further.
In the hemorrhagic stroke cohort, for obvious rea-
sons (N)OAC use after implant and during follow-up 
was much lower than for the total population, while 
stroke rate reduction was the same and major bleed-
ing rate was 67% less than historic data. In this patient 
population, the optimal stroke prevention strategy with 
anticoagulation is the topic of ongoing debate among 
neurologists. Although recurrence of hemorrhagic 
stroke can be up to 9%, (N)OAC therapy is often rein-
stated after recovery of the index event.20 Conversely, 
many patients are prescribed with APT or nothing as 
in some forms of cerebral disease the risk of recur-
rence is considered too high. Randomized studies like 
APACHE-AF (Apixaban Versus Antiplatelet Drugs or No 
Antithrombotic Drugs After Anticoagulation-Associat-
ed Intracerebral Haemorrhage in Patients With Atrial 
Fibrillation)21 are ongoing to determine the efficacy and 
safety of NOAC or ASA strategies. Nonetheless, some 
patients seem to become exposed to a bleeding risk 
again, while others may remain unprotected for isch-
emic stroke. Recent propensity-matched data from 
Nielsen-Kudsk et al22 suggested that the combination of 
D
ow
nloaded from
 http://ahajournals.org by on July 11, 2019
Boersma et al; EWOLUTION WATCHMAN LAAO
Circ Arrhythm Electrophysiol. 2019;12:e006841. DOI: 10.1161/CIRCEP.118.006841 March 2019 11
LAAO with SAPT therapy had a strikingly lower stroke 
risk as well as hemorrhagic stroke recurrence, com-
pared with conventional therapy ranging from (N)OAC 
to APT to nothing. More evidence in this population 
will be coming from the randomized STROKECLOSE 
study  (Prevention of Stroke by Left Atrial Appendage 
Closure in Atrial Fibrillation Patients After Intracerebral 
Hemorrhage) that is ongoing.
Bleeding and Anticoagulation
In EWOLUTION actual major bleeding rates of 2.7 per 
100 patient-years were almost half compared with 
historic data based on HAS-BLED scores with nonval-
vular AF patients on warfarin therapy.11 Bleeding risk 
was highest during the more intense phase of OAC. 
Although the low major bleeding rate appears favor-
able, it seems desirable to achieve even lower bleeding 
rates by further diminishing the use of anticoagulants. 
Interestingly, an analysis of the DAPT cohort in EWOLU-
TION showed that early DAPT discontinuation preserved 
the stroke rate reduction, while lowering the rate of 
bleeding at 1 year by 69%.23 However, aside from the 
perceived risk of DRT, one should realize that there are 
competing comorbidities necessitating the concomitant 
use of even DAPT in many patients.
In view of the favorable results on stroke reduction 
with lower bleeding risks in the large NOAC against 
warfarin trials, some argue that there is a need to repeat 
randomized trials against LAAO. However, especially in 
those with a contraindication to anticoagulation that 
currently constitute the main LAAO population, there 
are ethical and practical considerations that make this 
difficult. In the AVERROES trial,12 AF patients with a 
contraindication (60%) or discontinued use of warfa-
rin (40%) showed higher stroke reduction by apixaban 
with similar bleeding risk compared with ASA. How-
ever, the recent NAVIGATE-ESUS (New Approach Riva-
roxaban Inhibition of Factor Xa in a Global Trial Versus 
ASA to Prevent Embolism in Embolic Stroke of Unde-
termined Source)24 in patients without AF and stroke of 
unknown origin was terminated prematurely because 
rivaroxaban had an excessive bleeding rate compared 
with ASA. In EWOLUTION, major bleeding rates were 
low, although there was a difference between sub-
groups. Patients with prior hemorrhagic stroke had a 
67% lower rate than expected and had the lowest use 
of (N)OAC and DAPT, while patients with prior isch-
emic stroke had a 41% reduction but more patients on 
(N)OAC and DAPT. Patients with a history of a major 
bleeding had a somewhat protracted risk reduction of 
30% compared with the highest historic HAS-BLED 
score in the study. Some argue that the inability to 
reduce bleeding by continued use of ASA is the Achilles 
heel of LAAO therapy. However, by their nature, some 
bleeding conditions will continue to cause events even 
without any use of OACs, and any reduction in events 
should be considered favorable. Current studies do not 
provide evidence of bleeding burden reduction by using 
APT instead of (N)OAC, but a strategy of the lower-the-
better seems the most logical option.
Limitations
Although this is a prospective registry with outside moni-
toring for data completeness, the clinical indications, 
clinical follow-up, and imaging were center dependent 
and the responsibility of local investigators. The lack of 
a control arm limits the full assessment of therapy ben-
efit in this patient population. Although the indication to 
install stroke prevention in daily practice is also based on 
CHA2DS2-VASc and HAS-BLED outcome data in historical 
patient cohorts, direct comparison to the current findings 
for WATCHMAN LAAO should be done with caution. The 
continued use of any form of OAC in 92% of the patients 
may also play a role in stroke/TIA/SE prevention.
Conclusions
The final 2-year follow-up of EWOLUTION shows that 
WATCHMAN LAAO is an effective and safe alternative 
to OAC in a population of nonvalvular AF patients at 
high risk for stroke and bleeding. The favorable effect 
was consistently observed even in patients with prior 
ischemic or hemorrhagic stroke and patients with a his-
tory of major bleeding, in the presence of a much lower 
use of anticoagulation compared with prior random-
ized controlled trials on WATCHMAN, as in this cohort 
73% were deemed unsuitable to use (N)OAC.
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